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What\'s new?The value of quality improvement programmes in the management of chronic conditions has been established in a number of prospective studies and meta‐analyses.The effect of the Joint Asia Diabetes Evaluation (JADE) programme, an information technology‐augmented integrated care model, on diabetes‐related outcomes has been demonstrated in several studies within developed healthcare systems.This study represents one of the few quality improvement initiatives undertaken in a developing country and is the first to answer the question of whether initiatives such as JADE are effective in enhancing quality of care in underfunded healthcare systems.Given the increasing demand for healthcare resources in developing countries, quality improvement has the potential to improve chronic care without substantial additional costs.

Introduction {#dme13164-sec-0006}
============

Achieving and maintaining recommended treatment targets decreases the risk of diabetes‐related vascular complications, mortality and associated healthcare costs [1](#dme13164-bib-0001){ref-type="ref"}, [2](#dme13164-bib-0002){ref-type="ref"}, [3](#dme13164-bib-0003){ref-type="ref"}, [4](#dme13164-bib-0004){ref-type="ref"}. In the UK Prospective Diabetes Study, an 11‐mmol/mol (1%) reduction in mean HbA~1c~ led to 21% fewer deaths, 14% fewer myocardial infarctions and a 37% decrease in microvascular complications [5](#dme13164-bib-0005){ref-type="ref"}. Despite collective accord, there are major treatment gaps attributable to suboptimum self‐care, poor adherence to treatment and clinical inertia, resulting in low rates of treatment target attainment in both developed and developing regions [6](#dme13164-bib-0006){ref-type="ref"}, [7](#dme13164-bib-0007){ref-type="ref"}.

These barriers are amplified by systemic factors, especially in developing countries. In China, for example, the majority of chronic care occurs in an in‐patient setting with most clinical assessments and treatment covered or reimbursed; however, in a primary or ambulatory care setting, many laboratory tests and chronic medications require co‐payments or are not reimbursed. Electronic medical systems exist but are largely fragmented, resulting in duplication or overlapping of consultations, investigations and medications. Despite an initiative to promote primary care by establishing community‐based clinics, many patients prefer going to hospitals for specialist care, with long waiting times and short contact intervals. Patients typically return every 1--2 months, mainly to collect medications, often without pre‐booking, assessment or education, and with high default rates [8](#dme13164-bib-0008){ref-type="ref"}, [9](#dme13164-bib-0009){ref-type="ref"}.

One area of focus is the lack of structure for documenting risk factors and complications, as well as the arbitrary nature of risk stratification and patient follow‐up. In the USA, the Institute of Medicine recommended the following strategies to improve chronic care: redesign care processes based on best practices, use information technology to manage clinical data with decision support, transfer knowledge and skills to team members to coordinate care and use performance and outcome measures for quality control [10](#dme13164-bib-0010){ref-type="ref"}. In a meta‐analysis of strategies for quality improvement, promotion of self‐care and team change were associated with a 4‐mmol/mol (0.37%) mean reduction in HbA~1c~, along with improvements in LDL cholesterol and blood pressure (BP) [11](#dme13164-bib-0011){ref-type="ref"}.

Since 1995, the Chinese University of Hong Kong (CUHK) Diabetes Care and Research Team has re‐designed workflows and trained nurses to assess patients and deliver protocol‐based care. By changing workflows and through task delegation, we were able to improve medication adherence, with attainment of multiple targets and reduced risks of cardiovascular‐renal complications [12](#dme13164-bib-0012){ref-type="ref"}, [13](#dme13164-bib-0013){ref-type="ref"}. Based on these prototypes, we designed the web‐based Joint Asia Diabetes Evaluation (JADE) portal, consisting of two modules. The comprehensive assessment (CA) module comprises templates for periodic assessment, risk stratification, personalized reporting and automated decision support. The follow‐up module includes templates for documentation of modifiable risk factors, hypoglycaemia and key events to track clinical progress and reinforce adherence [14](#dme13164-bib-0014){ref-type="ref"}. A separate portal with a CA module identical to that of JADE, was also created to help doctors establish a diabetes monitoring database (DIAMOND) as a first step towards a comprehensive quality improvement programme. In this demonstration project, we examined the effectiveness of delivering integrated care in China with or without nurse‐coordinated follow‐up visits using the JADE and DIAMOND portals, respectively, on cardiometabolic control and health behaviours, including default rates.

Patients and methods {#dme13164-sec-0007}
====================

The study assessed a 1‐year multicentre randomized non‐blinded quality improvement programme. Between January 2009 and September 2010, patients with Type 2 diabetes aged ≥ 18 years were recruited from six tertiary hospitals in China. Exclusion criteria included Type 1 diabetes, life‐threatening conditions, reduced life expectancy or inability to understand the scope of the study. The study was approved by the New Territories East Cluster Clinical Research Ethics Committee and local institutional ethics boards at each participating site. All participants provided written informed consent.

A total of 3586 eligible patients were randomized in a 1:1 ratio to DIAMOND (CA only) or JADE (CA plus nurse‐coordinated structured follow‐up). At each centre, randomization was performed using computer‐generated codes kept in sealed, opaque envelopes, numbered 1 to 600 prefixed by the study site. Personnel at the site not participating in the study opened the envelope and informed consenting participants of their group assignment.

Each centre was given a grant to support an additional CUHK project team‐trained nurse to perform the CA, guided by the JADE/DIAMOND portals and supervised by a physician. Both doctors and nurses received training on the use of the portals to perform a structured patient evaluation, document care processes and communicate results of clinical and laboratory assessments to participants. For participants randomized to JADE, the additional nurse was trained to use the follow‐up module to manage follow‐up appointments and facilitate ongoing patient support between clinic visits, while the DIAMOND group received usual care. Details of the JADE programme have been published and are included in Appendix S1 [15](#dme13164-bib-0015){ref-type="ref"}. The CA report consists of 5‐year probabilities for coronary heart disease, heart failure, stroke and end‐stage renal disease, estimated using validated risk equations [16](#dme13164-bib-0016){ref-type="ref"}, [17](#dme13164-bib-0017){ref-type="ref"}, [18](#dme13164-bib-0018){ref-type="ref"}, [19](#dme13164-bib-0019){ref-type="ref"}. Patients were classified into one of four risk categories based on risk scores derived from risk equations, presence or absence of cardiovascular‐renal disease, and an ensemble of metabolic risk factors. Each risk category corresponded to a recommended care level that determined frequency of structured follow‐up visits and intensity of care [14](#dme13164-bib-0014){ref-type="ref"}.

Automated reports provided to patients and physicians contained trend lines of attained versus recommended metabolic targets, 5‐year probabilities of major events, and risk categories. The physician report included triggered reminders on treatment intensification, while the patient report included practice tips to promote lifestyle changes, treatment adherence and self‐monitoring, in the local language. Both participants and referring doctors in the DIAMOND group received their respective reports followed by usual care. Participants assigned to JADE were recommended to receive 2--4 h of diabetes education and at least two additional contacts by the nurse coordinator (telephone or face‐to‐face visits). Facilitated by the follow‐up module, nurses were asked to reinforce treatment and lifestyle adherence, encourage self‐monitoring of blood glucose (SMBG) and remind them about structured follow‐up appointments that included documentation of laboratory measurements, body weight, blood pressure, hypoglycaemia, self‐care and other major events in the JADE portal. The nurse coordinator issued a follow‐up report, discussed cardiometabolic control and clarified concerns regarding therapy. Participants in the lower risk categories (l or 2, with few risk factors/complications) were recommended to have structured follow‐up visits every 4--6 months and those in higher risk categories (3 or 4, with multiple risk factors and/or complications) every 2--3 months. At the end of 12 months, all participants underwent repeat CA, and non‐returnees were contacted by telephone to ascertain health status.

The primary outcome was the proportion of participants attaining ≥ 2 treatment targets (HbA~1c~ \< 53 mmol/mol (7%), BP \< 130/80 mmHg, LDL cholesterol \< 2.6 mmol/l) after 12 months. Other outcomes included default rates, change in quality‐of‐life measures, frequency of hypoglycaemia, adherence to lifestyle modification/self‐care activities, and new onset of physician‐documented diabetes‐related endpoints. Events were recorded using standard forms, with predefined diagnosis accompanied by a narrative, albeit not adjudicated. Power calculation and statistical analyses applied are available in Appendix S2.

Results {#dme13164-sec-0008}
=======

Between January 2009 and September 2010, 3586 eligible participants, representing \~65% of all subjects considered \[mean age 56.5 ± 11.6 years, 54.4% men, median (interquartile range) disease duration of 5 (1--10) years, mean HbA~1c~ 62 ± 22 mmol/mol (7.85 ± 2.02%)\] were recruited from patients already receiving treatment at the clinics. The primary reasons for declining were testing costs and recurring travel to study site. A total of 1728 participants were assigned to DIAMOND and 1858 to JADE, with both groups having similar characteristics at baseline (Table [1](#dme13164-tbl-0001){ref-type="table-wrap"}).

###### 

Baseline characteristics of all randomized Chinese patients with type 2 diabetes

                                                              *n*     DIAMOND                        JADE                    *P*
  ----------------------------------------------------------- ------- ----------------------- ------ ----------------------- -------
  Number randomized                                                   1728                           1858                    
  **Demographics**                                                                                                           
  Mean ± [sd]{.smallcaps} age, years                          1728    56.8 ± 11.7             1858   56.1 ± 11.6             0.096
  Gender: men, *n* (%)                                        1728    941 (54.5)              1858   1011 (54.4)             0.98
  Median (IQR) disease duration, years                        1705    5.0 (1.0, 10.0)         1809   5.0 (1.0, 10.0)         0.725
  Education, *n* (%)                                          1724                            1849                           0.001
  \< 6 years                                                          168 (9.7)                      132 (7.1)               
  6--11 years                                                         415 (24.0)                     424 (22.8)              
  \> 11 years                                                         1140 (66.0)                    1291 (69.5)             
  Unemployed, *n* (%)                                         1724    1103 (64.0)             1850   1153 (62.3)             0.306
  Tobacco use, *n* (%)                                        1712                            1827                           0.998
  Never                                                               1123 (65.6)                    1202 (65.8)             
  Former                                                              206 (12.0)                     208 (11.4)              
  Current                                                             383 (22.4)                     417 (22.8)              
  Alcohol use, *n* (%)                                        1718                            1830                           0.773
  Never                                                               1187 (69.1)                    1269 (69.3)             
  Physical activity ≥ 3 times/week, *n* (%)                   1717    867 (50.5)              1849   991 (53.6)              0.064
  SMBG ≥ weekly, *n* (%)                                      1576    677 (43.0)              1713   780 (45.5)              0.137
  Adherence to balanced diet, *n* (%)                         1719    1091 (63.5)             1852   1205 (65.1)             0.156
  Median (IQR) follow‐up, months                              1728    12.5 (5.28)             1858   12.5 (3.98)             0.449
  **Complications and comorbidities**,*n* (%)                                                                                
  Retinopathy                                                 1681    228 (13.6)              1808   241 (13.3)              0.84
  Sensory neuropathy                                          1722    143 (8.3)               1852   113 (6.1)               0.011
  Chronic kidney disease, *n* (%)                             1646    37 (2.2)                1789   37 (2.1)                0.717
  All heart events including heart failure, *n* (%)           1726    164 (9.5)               1845   155 (8.4)               0.221
  Stroke, *n* (%)                                             1720    54 (3.1)                1850   42 (2.3)                0.109
  Peripheral vascular disease, *n* (%)                        1556    164 (10.5)              1688   122 (7.3)               0.001
  **Risk categories**,*n* (%)                                 0.483                                                          
  Low: 1/2                                                    1727    220 (12.7)              1855   251 (13.5)              
  High: 3/4                                                   1727    1507 (87.3)             1855   1604 (86.5)             
  **Treatments**,*n* (%)                                                                                                     
  Lifestyle modification only                                 1728    385 (22.3)              1858   388 (20.9)              0.309
  On oral antidiabetic drug                                   1728    1214 (70.3)             1858   1321 (71.1)             0.579
  Insulin                                                     1728    452 (26.2)              1858   512 (27.6)              0.345
  Any BP drugs                                                1728    390 (22.6)              1858   420 (22.6)              0.98
  Angiotensin‐converting enzyme inhibitors                    1728    33 (1.9)                1858   34 (1.8)                0.86
  Angiotensin II receptor type 1 receptor blocker             1728    207 (12.0)              1858   220 (11.8)              0.898
  Statins                                                     1728    544 (31.5)              1858   597 (32.1)              0.676
  **Risk factor control**                                                                                                    
  Mean ± [sd]{.smallcaps} body weight, kg                     1715    69.52 ± 12.67           1845   69.57 ± 12.62           0.911
  Mean ± [sd]{.smallcaps} waist circumference, cm                                                                            
  Women                                                       682     87.15 ± 9.97            713    85.96 ± 10.19           0.028
  Men                                                         800     91.46 ± 9.68            815    91.81 ± 9.48            0.47
  Mean ± [sd]{.smallcaps} BMI (kg/m^2^)                       1715    25.32 ± 3.62            1845   25.18 ± 3.58            0.246
  Mean ± [sd]{.smallcaps} diastolic BP (mmHg)                 1694    78.4 ± 10.4             1824   78.8 ± 11.0             0.243
  Mean ± [sd]{.smallcaps} systolic BP (mmHg)                  1694    125.8 ± 15.8            1824   125.0 ± 15.7            0.131
  Mean ± [sd]{.smallcaps} total cholesterol, mmol/l           1653    4.95 ± 1.31             1785   4.91 ± 1.16             0.47
  Mean ± [sd]{.smallcaps} HDL cholesterol, mmol/l                                                                            
  Women                                                       751     1.26 ± 0.31             799    1.29 ± 0.34             0.06
  Men                                                         891     1.1 ± 0.28              960    1.12 ± 0.27             0.108
  Mean ± [sd]{.smallcaps} LDL cholesterol, mmol/l             1644    2.94 ± 0.89             1768   2.92 ± 0.88             0.446
  Mean ± [sd]{.smallcaps} haemoglobin, g/dl                   1446    14.49 ± 7.44            2545   14.31 ± 5.77            0.443
  Mean ± [sd]{.smallcaps} HbA~1c~, % (mmol/mol)               1648    7.91 (53) ± 2.08 (15)   1788   7.78 (59) ± 1.95 (15)   0.057
  Median (IQR) triglyceride, mmol/l                           1654    1.54 (1.14)             1788   1.48 (1.22)             0.005
  Median (IQR) urine albumin to creatinine ratio, mg/mmol     1506    1.20 (2.75)             1606   1.25 (2.85)             0.059
  Mean ± [sd]{.smallcaps} estimated GFR, ml/min/1.73 m^2^     1646    122.2 ± 38.74           1789   122.63 ± 41.88          0.754
  Obesity, *n* (%)                                            1539    1081 (70.2)             1607   1114 (69.3)             0.575
  Dyslipidaemia, *n* (%)                                      1669    1551 (92.9)             1810   1668 (92.2)             0.385
  Hypertension, *n* (%)                                       1707    1275 (74.7)             1835   1392 (75.9)             0.421
  Macroalbuminuria, *n* (%)                                   1506    75 (5.0)                1606   89 (5.5)                0.64
  Microalbuminuria, *n* (%)                                   1506    330 (21.9)              1606   385 (24.0)              0.322
  Frequency of hypoglycaemic episodes ≥ once/month, *n* (%)   1713    178 (10.4)              1847   185 (10.0)              0.712
  **Attainment of treatment targets**,*n* (%)                                                                                
  HbA~1c~ \< 7.0% (53 mmol/mol)                               1648    692 (42.0)              1788   811 (45.4)              0.047
  BP \< 130/80 (mmHg)                                         1694    662 (39.1)              1824   710 (38.9)              0.926
  LDL cholesterol \< 2.6 (mmol/l)                             1644    600 (36.5)              1768   644 (36.4)              0.966
  At least one target                                         1595    1211 (75.9)             1716   1300 (75.8)             0.911
  At least two targets                                        1595    555 (34.8)              1716   624 (36.4)              0.347
  All three targets                                           1595    105 (6.6)               1716   136 (7.9)               0.137
  **Quality of life**                                                                                                        
  Mean ± [sd]{.smallcaps} EQ‐VAS                              1715    83.01 ± 12.10           1830   82.83 ± 12.35           0.721
  Mean ± [sd]{.smallcaps} EQ‐5D index                         1708    0.91 ± 0.13             1817   0.91 ± 0.14             0.995

BP, blood pressure; DIAMOND, DIAbetes MONitoring Database; IQR, interquartile range; JADE, Joint Asia Diabetes Evaluation; SMBG, self‐monitoring of blood glucose; VAS, visual analogue scale.

John Wiley & Sons, Ltd

Between March 2011 and December 2013, after a median (interquartile range) follow‐up of 12.5 (4.6) months, 2559 out of 3586 randomized participants (71.4%) returned for the second CA (CA2), with documentation of clinical and biochemical data and event rates. A total of 1027 participants (28.6%) did not return for CA2, but 636 of those were contacted by telephone for ascertainment of health status, while 371 (10.3%) were lost to follow‐up with no vitality ascertainment. In all, 24 participants had a cardiovascular event and 12 died. A final total of 2559 participants were included in the per‐protocol analysis (Fig. [1](#dme13164-fig-0001){ref-type="fig"}).

![Randomization and disposition of patients included in the intend to treat and per protocol analyses.](DME-34-440-g001){#dme13164-fig-0001}

In the JADE group, 191 participants were in risk category 1--2, with the remaining 1192 in risk category 3--4. The mean frequencies of nurse‐coordinated follow‐up visits in risk categories 1--4 were 1.2, 1.8, 1.9 and 2.4 times per year, respectively. Follow‐up frequency for patients in DIAMOND was not captured because the DIAMOND portal was not designed to capture follow‐up frequency.

Compared with baseline, the proportion of participants attaining ≥ 2 treatment targets (DIAMOND 38.2 to 50.8%, *P* \< 0.01; JADE 40.6 to 50.0%, *P* \< 0.01); HbA~1c~ \< 53 mmol/mol (7%) (DIAMOND 45.8 to 61.1%, *P* \< 0.01, JADE 49.0 to 58.5%, *P* \< 0.01) and LDL cholesterol \< 2.6 mmol/l (DIAMOND 36.4 to 52.9%, *P* \< 0.01; JADE 39.5 to 53.4%, *P* \< 0.01) increased similarly, with no between‐group difference (Fig. [2](#dme13164-fig-0002){ref-type="fig"}). The absolute change in HbA~1c~ \[DIAMOND −8 mmol/mol, JADE −7 mmol/mol (DIAMOND −0.69%, JADE −0.62%); *P* = 0.473\] and LDL cholesterol (DIAMOND −0.32 mmol/l, JADE −0.28 mmol/l; *P* = 0.286) was similar in each group (Table [2](#dme13164-tbl-0002){ref-type="table-wrap"}). The proportion of participants with BP \< 130 mmHg fell in the DIAMOND group but remained unchanged in the JADE group (DIAMOND 40.6 to 34.6%, *P* \< 0.01; JADE 39.2 to 37.4%, *P* = 0.239) with no between‐group difference (Fig. [2](#dme13164-fig-0002){ref-type="fig"}). More patients had a reduction in systolic BP of ≥ 10 mmHg (DIAMOND 18.4 vs JADE 22.2%; *P* = 0.052) and in diastolic BP of ≥ 5 mmHg (DIAMOND: 26.6% vs JADE: 33.5%, *P* = 0.018) in the JADE than the DIAMOND group (Table [2](#dme13164-tbl-0002){ref-type="table-wrap"}).

![Proportions of patients in the Diabetes Monitoring Database (DIAMOND) and Joint Asia Diabetes Evaluation (JADE) groups attaining treatment targets at repeat assessment after 1 year of follow‐up. Between‐group comparisons adjusted for trial centre, age, gender, disease duration and baseline value. All *P*‐values for within‐group comparison (CA2 vs baseline) were *P* \< 0.01 except that of JADE on blood pressure (BP) \< 130/80 mmHg (*P* = 0.239). No significant difference for changes in target achievement between groups. Only patients with paired data for baseline and second comprehensive assessment (CA2) are included in analysis. SMBG, self‐monitoring of blood glucose.](DME-34-440-g002){#dme13164-fig-0002}

###### 

Mean changes for HbA~1c~, blood pressure, lipids and quality of life measures as well as changes in medications and self‐care behaviour in the DIAMOND and JADE groups who underwent comprehensive assessments at baseline and after 12 months

  Month 12: baseline visit                                                 Valid number   DIAMOND (95% CI)        Valid number   JADE (95% CI)          Crude *P* value   Adjusted *P* value[a](#dme13164-note-0003){ref-type="fn"}
  ------------------------------------------------------------------------ -------------- ----------------------- -------------- ---------------------- ----------------- -----------------------------------------------------------
  **Metabolic control**                                                                                                                                                   
  Median (IQR) HbA~1c~, mmol/mol                                           944            −8 (−9, −7)             1112           −7 (−8, −6)            0.372             0.473
  Median (IQR) HbA~1c~, %                                                  944            −0.69 (−0.81, −0.57)    1112           −0.62 (−0.73, −0.50)   0.372             0.473
  Median (IQR) SBP, mmHg                                                   1130           2.43 (1.49, 3.37)       1326           1.64 (0.77, 2.50)      0.221             0.091
  Median (IQR) DBP, mmHg                                                   1130           0.25 (−0.37, 0.86)      1326           −1.03 (−1.65, −0.41)   0.004             0.057
  Median (IQR) LDL cholesterol, mmol/l                                     924            −0.32 (−0.38, −0.27)    1023           −0.28 (−0.34, −0.23)   0.335             0.286
  Median (IQR) body weight, kg                                             1148           −0.13 (−0.48, 0.22)     1353           −0.02 (−0.29, 0.25)    0.612             0.482
  HbA~1c~ reduction ≥ 0.5%, *n* (%)                                        944            400 (42.4)              1112           420 (37.8)             0.034             0.223
  Systolic BP reduction ≥ 10 mmHg, *n* (%)                                 1130           208 (18.4)              1326           294 (22.2)             0.021             0.052
  Diastolic BP reduction ≥ 5 mmHg, *n* (%)                                 1130           301 (26.6)              1326           444 (33.5)             \< 0.001          0.018
  LDL cholesterol reduction ≥ 30%, *n* (%)                                 924            193 (20.9)              1023           206 (20.1)             0.682             0.511
  Body weight reduction ≥ 3%, *n* (%)                                      1148           232 (20.2)              1353           259 (19.1)             0.503             0.344
  Smoking cessation, *n* (%)                                               205            16 (7.8)                199            21 (10.6)              0.346             0.759
  **Add on medication** [b](#dme13164-note-0004){ref-type="fn"}, *n* (%)                                                                                                  
  Insulin                                                                                 50/885 (5.6)                           71/1027 (6.9)          0.295             0.175
  Oral antidiabetic drug                                                                  67/350 (19.1)                          96/383 (25.1)          0.199             0.041
  BP‐lowering drugs                                                                       63/894 (7.1)                           55/1072 (5.1)          0.098             0.126
  Lipid‐regulating drugs                                                                  106/793 (13.4)                         110/899 (12.2)         0.337             0.586
  **Quality of life**                                                                                                                                                     
  Median (IQR) EQ‐5D index                                                 1039           0.028 (0.018, 0.038)    992            0.037 (0.027, 0.047)   0.192             0.146
  Median (IQR) EQ‐VAS                                                      1001           −0.80 (−1.52, −0.086)   967            0.66 (−0.12, 1.44)     0.005             0.478

BP, blood pressure; DIAMOND, DIAbetes MONitoring Database; IQR, interquartile range; JADE, Joint Asia Diabetes Evaluation.

Adjusted for age, gender, disease duration, baseline value and trial centre.

New users/non users at baseline.

John Wiley & Sons, Ltd

Both groups reported improved adherence to self‐care behaviours (*P* \< 0.01 compared with baseline) with more patients in the JADE group performing SMBG at study end (50.5 vs 44.2%, *P* = 0.005; Fig. [1](#dme13164-fig-0001){ref-type="fig"}). In the DIAMOND group, 16 of 205 participants (7.8%) and 21 of 199 (10.6%) in the JADE group stopped smoking, with no between‐group difference (Table [2](#dme13164-tbl-0002){ref-type="table-wrap"}).

At study end, more participants in the JADE group initiated oral antidiabetic drug treatment (DIAMOND 19.1% vs JADE 25.1%; *P* = 0.041). New use of antihypertensive/lipid‐lowering drugs was significantly different from baseline but similar in both groups. The proportion of participants reporting hypoglycaemic episodes at least monthly fell similarly in both groups (DIAMOND 11.9 to 6.7%, *P* \< 0.001; JADE 10.8 to 7.3%, *P* = 0.002). Scores on the EuroQol health status index, the EQ‐5D (visual analogue scale), tended to improve in the JADE group and declined in the DIAMOND group, with no between‐group difference.

Amongst returnees for CA2, the rate of incident diabetes‐related complications including, chronic kidney disease, sensory neuropathy, foot ulcer, loss of visual acuity or advanced eye disease, were similar between groups (Table [3](#dme13164-tbl-0003){ref-type="table-wrap"}).

###### 

New onset of diabetes‐related endpoints in JADE and DIAMOND study groups

                                                                                            *n*    DIAMOND, *n* (%)   *n*    JADE, *n* (%)
  ----------------------------------------------------------------------------------------- ------ ------------------ ------ ---------------
  **All patients with vitality status**                                                     1549                      1646   
  Self‐reported new cardiovascular event (coronary heart disease or stroke)                        30 (1.9)                  42 (2.5)
  Returnees                                                                                 1176   21 (1.8)           1383   27 (2.0)
  Non‐returnees                                                                             373    9 (2.4)            263    15 (5.7)
  Death                                                                                            6 (0.3)                   6 (0.18)
  **Returnees for repeat assessment**                                                       1176                      1383   
  New chronic kidney disease: 50% loss of estimated GFR                                     900    16 (1.8)           1026   12 (1.2)
  New appearance of sensory neuropathy in patients without sensory neuropathy at baseline   1072   49 (4.6)           1048   52 (5.0)
  Remission of sensory neuropathy in patients with sensory neuropathy at baseline           96     70 (72.9)          75     53 (70.7)
  Worsening or new appearance of diabetic retinopathy                                       992    28 (2.8)           869    37 (4.3)
  Improvement of diabetic retinopathy in patients with diabetic retinopathy at baseline     59     59 (100)           45     41 (91.1)
  Improved visual acuity in at least one eye                                                563    164 (29.1)         657    228 (34.7)
  Deteriorated visual acuity in at least one eye                                            570    216 (37.9)         658    239 (36.3)

DIAMOND, DIAbetes MONitoring Database; JADE, Joint Asia Diabetes Evaluation.

Worsening /improvement of diabetic retinopathy is defined as advancement or stabilization in the grading by ophthalmologist (pre‐proliferative, proliferative, advanced).

*n* includes returnees and a subset of defaulters who could be reached for health status assessment at study end.

John Wiley & Sons, Ltd

There were fewer defaulters in the JADE group than in the DIAMOND group (25.6 vs 32.0%; *P* \< 0.001). At baseline, defaulters were younger (55.8 vs 56.7 years; *P* = 0.036), were more likely to have a positive smoking history (35.2 vs 33.9%; *P* = 0.002), were less well educated (\> 11 years\' education, 61.40 vs 70.70%; *P* = 0.017), and had worse cardiometabolic risk profile and higher rates of chronic kidney disease (3.20 vs 1.70%; *P* = 0.007) and macroalbuminuria (8.10 vs 4.20%; *P* \< 0.001), despite similar disease duration. Although defaulters were more likely to be treated with insulin (30.70 vs 25.30%; *P* = 0.001) and lipid‐lowering drugs (38.20 vs 33.90%; *P* = 0.016), they were less likely to adhere to regular physical exercise (46.10 vs 54.50%; *P* \< 0.001) and achieve HbA~1c~ target (37.20 vs 46.40%; *P* \< 0.001) or ≥ 2 treatment targets (30.60 vs 37.40%; *P* \< 0.001; Table [4](#dme13164-tbl-0004){ref-type="table-wrap"}).

###### 

Population characteristics at baseline for returnees versus defaulters

                                                            Returnees               Defaulters              *P*
  --------------------------------------------------------- ----------------------- ----------------------- ----------
  Total number of participants, *n* (%)                     2559 (71.4)             1027 (28.6)             --
  **Demographics**                                                                                          
  Mean ± [sd]{.smallcaps} age, years                        56.70 ± 11.56           55.80 ± 11.83           0.036
  Women, %                                                  54.4                    54.5                    0.942
  Education, %                                              \< 0.001                                        
  \< 6 years                                                6.7                     12.7                    
  6--11 years                                               11.6                    11.8                    
  \> 11 years                                               70.7                    61.4                    
  Unemployed, %                                             64.2                    60.5                    0.041
  Smoking, %                                                0.428                                           
  Never                                                     66.1                    64.8                    
  Former                                                    11.6                    11.8                    
  Current                                                   22.3                    23.4                    
  Alcohol consumption, %                                    0.002                                           
  Never                                                     67.8                    72.8                    
  Former                                                    6.4                     7.5                     
  Occasional                                                16.9                    11.7                    
  Regular                                                   8.9                     8.0                     
  Physical activity ≥ 3 times per week, %                   54.5                    46.1                    \< 0.001
  SMBG ≥ weekly, %                                          45.1                    42.4                    0.163
  Mean ± [sd]{.smallcaps} disease duration, years           6.43 ± 6.40             6.22 ± 6.11             0.369
  **Complications and comorbidities, %**                                                                    
  Chronic kidney disease                                    1.7                     3.2                     0.007
  Coronary heart disease                                    9.0                     8.4                     0.548
  Stroke                                                    3.0                     1.9                     0.052
  Peripheral vascular disease                               9.5                     7.3                     0.052
  Retinopathy                                               13.9                    12.5                    0.282
  Sensory neuropathy                                        7.0                     7.6                     0.489
  **Risk categories**                                       0.101                                           
  Low (1/2)                                                 13.8                    11.7                    
  High (3/4)                                                86.2                    88.3                    
  **Treatments, %**                                                                                         
  Lifestyle modification only                               21.2                    22.3                    0.487
  On oral antidiabetic drug                                 71.4                    69.0                    0.163
  Insulin                                                   25.3                    30.7                    0.001
  On lipid drugs                                            33.9                    38.2                    0.016
  Statins                                                   30.7                    34.7                    0.021
  On BP drugs                                               23.2                    21.0                    0.154
  ACE inhibitors                                            2.0                     1.6                     0.386
  AT1 receptor blockers                                     12.3                    11.0                    0.279
  **Risk factor control**                                                                                   
  Mean ± [sd]{.smallcaps} body weight, kg                   69\. 68 ± 12.34         69.19 ± 13.36           0.308
  Mean ± [sd]{.smallcaps} BMI, kg/m^2^                      25.68 ± 3.58            25.16 ± 3.64            0.361
  Mean ± [sd]{.smallcaps} waist circumference, cm                                                           
  Women                                                     86.50 ± 10.11           86.68 ± 9.90            0.769
  Men                                                       91.44 ± 9.38            92.09 ± 10.04           0.214
  Mean ± [sd]{.smallcaps} diastolic BP, mmHg                77.77 ± 9.6             77.76 ± 9.58            0.977
  Mean ± [sd]{.smallcaps} systolic BP, mmHg                 126.03 ± 15.07          126.72 ± 15.48          0.225
  Mean ± [sd]{.smallcaps} total cholesterol, mmol/l         4.90 ± 1.18             4.99 ± 1.37             0.073
  Mean ± [sd]{.smallcaps} HDL cholesterol, mmol/l                                                           
  Women                                                     1.29 ± 0.32             1.26 ± 0.33             0.118
  Men                                                       1.12 ± 0.28             1.08 ± 0.27             0.001
  Mean ± [sd]{.smallcaps} LDL cholesterol, mmol/l           2.90 ± 0.86             3.00 ± 0.94             0.005
  Mean ± [sd]{.smallcaps} haemoglobin, g/dl                 14.44 ± 6.85            14.27 ± 6.05            0.524
  Mean ± [sd]{.smallcaps} HbA~1c~, % (mmol/mol)             7.70 (61) ± 1.91 (14)   8.20 (66) ± 2.24 (17)   \< 0.001
  Median (IQR) triglyceride, mmol/l                         4.80 (4.15, 5.53)       4.88 (4.19, 5.58)       0.286
  Median (IQR) urine albumin to creatinine ratio, mg/mol    1.19 (0.65, 3.25)       1.35 (0.62, 4.23)       0.059
  Mean ± [sd]{.smallcaps} estimated GFR, ml/min/1.73 m^2^   120.7 ± 39.6            126.7 ± 42.1            \< 0.001
  Obesity, %                                                69.3                    70.7                    0.447
  Dyslipidaemia, %                                          92.4                    92.7                    0.755
  Hypertension, %                                           75.6                    74.6                    0.542
  Macroalbuminuria, %                                       4.2                     8.1                     \< 0.001
  Microalbuminuria, %                                       22.8                    23.3                    0.791
  **Attainment of treatment targets**, %                                                                    
  HbA~1c~ \< 7.0% (53 mmol/mol)                             46.4                    37.2                    \< 0.001
  BP \< 130/80 mmHg                                         50.0                    47.1                    0.154
  LDL cholesterol \< 2.6 mmol/l                             37.1                    34.8                    0.206
  At least one target                                       72.7                    70.4                    0.171
  At least two targets                                      37.4                    30.6                    \< 0.001
  All three targets                                         7.9                     5.3                     0.006
  **Quality of life**                                                                                       
  Mean ± [sd]{.smallcaps} EQ‐VAS score                      83.38 ± 11.97           81.75 ± 12.80           \< 0.001
  Mean ± [sd]{.smallcaps} EQ‐5D index score                 0.91 ± 0.14             0.92 ± 0.14             0.156

BP, blood pressure; IQR, interquartile range; JADE, Joint Asia Diabetes Evaluation; SMBG, self‐monitoring of blood glucose.
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Discussion {#dme13164-sec-0009}
==========

In this 12‐month randomized quality improvement programme in Chinese patients with Type 2 diabetes, we used a multi‐component web‐based portal to integrate care delivery focusing on workflow, task delegation and information technology. Irrespective of nurse support, both groups had improved cardiometabolic control, increased attainment of multiple treatment targets, enhanced self‐care and smoking cessation. The additional contacts by nurses during the follow‐up period did not further improve cardiometabolic control but reduced default rates and improved SMBG.

Given the multi‐component nature of the JADE/DIAMOND programme, it was challenging to identify the specific components that drove treatment effects, although these elements are known to individually and collectively improve diabetes care [11](#dme13164-bib-0011){ref-type="ref"}. In a 7‐year observational study consisting of 172 patients with Type 2 diabetes without history of cardiovascular‐renal complications, structured care provided by a diabetologist‐nurse team reduced cardiovascular‐renal disease and mortality by 50--70% compared with those attended by generalists in the medical clinic within the same institution [20](#dme13164-bib-0020){ref-type="ref"}. In another study evaluating peer empowerment in participants who also received structured care through the JADE programme, HbA~1c~ was reduced by 0.3% (3 mmol/mol), with improvement in multiple targets attained and self‐care [21](#dme13164-bib-0021){ref-type="ref"}.

The addition of nurse‐coordinated follow‐up visits in the JADE group did not further enhance glycaemic control or target attainment. That said, JADE participants were more likely to have stable BP control and increased SMBG and were less likely to default, suggesting that ongoing support can be translated into beneficial actions. The nurse provided was envisaged to take on a multifunctional role to promote adherence to the care protocol and reinforce patient education. Given the translational nature of this study that examined integrated care in real‐world settings, we used data documented in the follow‐up module of the JADE portal to assess protocol adherence. We did not rigorously enforce and strictly record compliance to protocol‐recommended practice; thus, it was not possible to fully appraise intervention fidelity.

In China, delivery of chronic care is fragmented and infrastructure and capacity for team‐based care are still evolving. Nurses for instance, are often tasked with simple procedures such as teaching insulin injection and SMBG or performing blood glucose tests. Furthermore, patients are less willing to engage nurses, preferring to consult directly with doctors. As such, their abilities to educate and empower patients may be less advanced compared with fully trained diabetes nurses. This may partially explain the lack of difference between the two groups. Also, the nurse coordinators in the present study received basic training in diabetes care, but, unlike case managers, were not empowered with treatment authority. In a meta‐analysis, quality improvement initiatives that included case managers authorized to adjust medications without awaiting physician approval substantially improved patient care [22](#dme13164-bib-0022){ref-type="ref"}.

Because cultural factors are an important component in education, we examined this result in light of education programmes implemented in Chinese populations. In a 1‐year prospective study in Hong Kong, a structured nurse education programme centred on cardiovascular disease risk every 3 months (mean total time 2.5 h) improved HbA~1c~, LDL cholesterol and BP (diastolic) compared with a control group [23](#dme13164-bib-0023){ref-type="ref"}. In Taiwan, the introduction of multidisciplinary care, combined with 2 h of diabetes education every 3 months for 1 year resulted in a 2‐mmol/mol (0.22%) reduction in HbA~1c~, with a nadir of 0.4% (4 mmol/mol) at 9 months, without changes in oral antidiabetic medications [24](#dme13164-bib-0024){ref-type="ref"}. In the JADE group, we also recommended nurses to deliver at least 2 h of education after the CA, but in a single session rather than multiple sittings. In a meta‐analysis, the benefit of patient self‐care education on HbA~1c~ was most pronounced immediately after the intervention, with effects waning by 1--3 months [25](#dme13164-bib-0025){ref-type="ref"}. In the Taiwanese study, subjects received initial diabetes education followed by repeated reinforcement sessions every 3 months for 1 year. The reduction in HbA~1c~ was evident at 3, 6 and 9 months but lost significance by 1 year, suggesting that physician or patient fatigue and loss of adherence may need to be addressed [24](#dme13164-bib-0024){ref-type="ref"}.

The fact that all participants benefitted from risk stratification with written feedback during the initial consultation might have contributed partially to a lack of separation and improvement in both groups. The proportion of participants with ≥ 2 treatment targets increased from 38.2 to 50.8% in the DIAMOND group and from 40.6 to 50.0% in the JADE group. Another reason for the lack of between‐group difference was patient‐structured follow‐up frequency in JADE. In the low‐risk category (care levels 1 and 2), the portal recommended 1--2 structured follow‐up visits per year and 4--5 visits for the high‐risk group (care levels 3 and 4). However, in the JADE group, the documented number of visits in the portal was 1.7 in participants at low risk and 2.0 in participants at high risk, the latter accounting for 86% of the JADE group. Given the fragmented nature of follow‐up medical visits in China, we anticipated the additional nurse‐coordinated visits to improve follow‐up frequency. The low number of these structured visits might have nullified the expected benefits, which highlights the challenges of implementing integrated care models in countries with traditional healthcare and financing systems. Moreover, patients\' perspectives need to be considered, as additional visits for a silent disease like diabetes may not be welcomed because of the extra time, tests and costs involved. By study design, there was no documentation of interval measurements between baseline and repeat CA2 in the DIAMOND group. Thus, although a variance might have existed between the two groups, the failure to fully comply a structured follow‐up and education programme in the JADE group might have attenuated these differences by study end. Similar observations have been reported previously [24](#dme13164-bib-0024){ref-type="ref"}, [25](#dme13164-bib-0025){ref-type="ref"}, [26](#dme13164-bib-0026){ref-type="ref"}.

Despite the lack of between‐group differences in cardiometabolic control, the default rate, defined *a priori*, was lower in the JADE than in the DIAMOND group. The defaulters had higher HbA~1c~ and LDL cholesterol, while concurrently were more likely to be prescribed insulin and lipid‐lowering drugs. Defaulters were younger, more likely to be in paid employment and were less likely to exhibit good self‐care behaviours. Patients less willing to participate in self‐care behaviours become increasingly dependent on polytherapy and with chronicity, drug regimens might become more complex, which could further exacerbate non‐adherence behaviours [27](#dme13164-bib-0027){ref-type="ref"}.

The present study has several limitations. Firstly, this was a real‐world application of integrated care augmented by information technology in China, where healthcare resources are limited. All six participating sites are leading centres, although many of the recommended tests in the CA were not reimbursed in an ambulatory setting. Unlike drug‐based clinical trials, none of the participants were compensated for their participation or diagnostic/care‐related expenditures. This might have led to selection of a more affluent population, although missing values for laboratory tests were found. As participating sites were selected from cosmopolitan cities, our findings cannot be extrapolated to rural populations. Secondly, while this was a randomized quality improvement programme, the treating doctors were not blinded to patient assignment and contamination was possible with participants in both the DIAMOND and JADE groups managed by the same physicians. Notwithstanding, the large sample size involving multiple centres, as well as the documentation of default rates/features known to be associated with higher mortality and treatment costs [28](#dme13164-bib-0028){ref-type="ref"}, [29](#dme13164-bib-0029){ref-type="ref"}, [30](#dme13164-bib-0030){ref-type="ref"} are major strengths.

In the present study, we did not observe enhanced cardiometabolic control with the addition of a nurse coordinator to the web‐based CA module, although we did observe a reduction in default rates and improved SMBG. We also verified that incorporating a quality improvement programme using an innovative care platform, such as the JADE programme, is both feasible and effective in a low‐resource setting, albeit not without challenges. This prototype allowed the combining of logistics, task delegation and information technology to increase the efficiency and effectiveness of integrated care delivery with improvements in cardiometabolic control and self‐care, as well as reduced clinical inertia.
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